Prostatic Neoplasm
73
8
11
46
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
16 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
9.6%
7 terminated out of 73 trials
86.8%
+0.3% vs benchmark
4%
3 trials in Phase 3/4
35%
16 of 46 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 46 completed trials
Clinical Trials (73)
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
EBRT + Lu-PSMA for N1M0 Prostate Cancer
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Investigation of Impact of AI on Prostate Cancer Workflow
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
PSMA PET Combined With MRI for the Detection of PCa
Impact of Augmented Reality During Robot-assisted Radical Prostatectomy
Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer
Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Prostate Cancer Genetic Risk Evaluation and Screening Study
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer